Trial Profile
A study to examine the serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactions.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Dec 2015
Price :
$35
*
At a glance
- Drugs Telaprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacodynamics
- 18 Dec 2015 New trial record